Please assess the completion status of the following clinical trial:

Trial Title: Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* in good general health.~* not pregnant and using effective birth control~* agreed to participate in entire study and comply with protocol requirements.~Exclusion criteria:~* military service prior to 1989.~* no previous smallpox vaccination.~* no contact with with children 1 year of age or younger~* immunodeficiency individuals or close contacts who are immunodeficient~* past history or current renal disease~* diagnosis or past history of eczema~* known allergy or past allergic reactions to latex gloves or to some antibiotics (neomycin, streptomycin, chlortetracycline, and polymyxin B).~* known allergy or past allergic to blood products.~* known allergy or past allergic reaction to cidofovir or sulfa-containing drugs.~* transfusion of blood or treatment with any blood product, including intramuscular or intravenous serum globulin within six months of the Screening Visit.~* serology positive for HIV, hepatitis B or hepatitis C.~* current diagnosis or history within six months of drug or alcohol abuse disorders, psychiatric illness.~* inoculation with any other live vaccine within 30 days of Day 0 or participation in another drug or vaccine trial within 30 days of Day 0.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 29 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): ACAM1000
- Group 2 (Type: EXPERIMENTAL): ACAM1000
- Group 3 (Type: EXPERIMENTAL): ACAM1000
- Group 4 (Type: ACTIVE_COMPARATOR): Dryvax

Based on this trial design, predict the completion outcome and termination type (if applicable).